最高の膵癌医師 - トップ132名の医師

Bülent Karagöz教授は膵臓癌を専門とし、33年の経験の経験とアナドル医療センターにおける900件以上の処置実績を有しています。

• 腫瘍生物学、免疫学、および分子標的がん治療の専門家
• イスタンブール・オカン大学医学部教授
• がん研究に関する40本以上の論文を発表
• 主要教育病院における腫瘍内科部長
• トルコ腫瘍内科学会会員

エダ・タンリクル医師は、アナドル医療センターで腫瘍内科を専門とし、膵臓癌の治療において21年の経験の経験を有しています。

• マルマラ大学にて腫瘍内科の研修を修了
• アナドル医療センターの腫瘍委員会メンバー
• 腫瘍学における国際臨床研究に参加
• ハイダルパシャ・ヌムネ研修研究病院にて腫瘍内科部長を歴任

Jaume Capdevila医師は、消化器および神経内分泌腫瘍を専門とするInstituto Oncológico Teknon의主任専門医として、1,100件以上の腫瘍学的治療を行ってきました。

• 26年の経験 の腫瘍内科における臨床経験
• 消化器および内分泌系悪性腫瘍の外科的治療を専門とする
• ウプサラ大学病院にて内分泌腫瘍学フェローシップを修了
• 腫瘍早期発見に関する50件以上の学術論文を執筆
• ESMO、ASCO、ENETS、EORTCの会員

低侵襲膵臓癌手術のパイオニアとして、腹腔鏡手術を12,000件以上執刀。権威あるDr. Ballesta腹腔鏡センターの創設者兼ディレクター。

• 消化器・膵臓外科を専門とする46年の経験の経験
• 精度向上のためのロボット支援ダ・ヴィンチ手術を実施
• 高度腹腔鏡技術において世界中の外科医を指導
• 外科的質においてIFSO認定卓越センターを取得
• 腹部外科に関する多数の論文を執筆

Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.

Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

パストラーナ医師は、ガレニア病院において膵臓癌を専門とする外科腫瘍学の資格認定医です。

• 外科腫瘍学における豊富な研修歴を持ち、Conacemにより資格認定を取得
• メキシコ腫瘍学会（SMEO）会員
• 2020年よりアナワク大学にて大学教員として勤務

Pfaffenbach教授は、ゾーリンゲン大学病院の消化器内科・腫瘍科長として、年間9,000件以上の内視鏡的介入を行っています。

• 内臓悪性腫瘍を専門とする
• 34年の経験の外科的および臨床的実務経験
• 腸管腫瘍学センター長
• 130本以上の論文著者
• 欧州消化器病学会会員

シャロン・ペレス医師は消化管腫瘍を専門とし、ロンドンの名高いロイヤル・マーズデン癌センターで研鑽を積みました。

• 膵癌手術およびウィップル手術の専門家
• 国際共同研究による臨床研究を実施
• 腹腔内温熱化学療法（HIPEC）および免疫療法などの高度治療を提供
• 腫瘍学の先進施設であるスーラスキー医療センター（イチロフ）に勤務

メリムスキー教授は膵臓癌を専門とし、スーラスキー医療センターにて数十年にわたる腫瘍学の経験を有しています。

• 軟部組織および骨腫瘍学の専門歴 41年の経験 年以上
• フェルスタイン医学研究センター上席研究員
• 欧州臨床腫瘍学会（ESMO）会員
• スーラスキー医療センター腫瘍科外来部門長

この医師は、消化管腫瘍の治療において30年以上の経験を持つ、著名な消化器専門医です。GIがんの予防、早期診断、および治療を専門としており、Sourasky Medical CenterのCancer Prevention Centerを率いています。

ヘブライ大学で一般医学の学位を取得し、テルアビブ大学で消化器学の専門を修了したこの医師は、NewYork-Presbyterian Centerで研究を行いました。この医師は300以上の論文を発表しており、American Association for Cancer ResearchやEuropean Society of Digestive Oncologyを含む、いくつかの著名な組織のメンバーです。

Activities • Prevention, research and early diagnosis of cancer • Palliative care in cancer • Cytotoxic chemotherapy • Hormontherapy • Targeted treatment • Immunotherapy Education • 2004 -2010 - Istanbul University, Istanbul faculty of medicine • 2011-2015 - Istanbul University, Istanbul faculty of medicine, internal medicine specialist • 2013-2014 - Cleveland Clinic Endocrinology Department, research associate • 2016-2019 Bezmiâlem Foundation University Medical Oncology Subdivision • Dissertation: Prognostic value of absolute monocyte count in patients with mantle cell lymphoma. • Subdivision Dissertation: An effect of adjuvant chemotherapy on lipid profile and anthropometric parameters in patients with breast and colon cancer. Publications • Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma. Aliyev A, Gupta M, et al. Endocr  18. • The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. • Aliyev A, Soundararajan S, Bucak E et al. Surgery.  • Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III-V thyroid cytology. Aliyev A, Patel J, Brainard J, et al. Surgery.2016 Jan;159(1):113-7. doi: 10.1016/j.surg.2015.06.063. Epub 2015 Oct 9. • Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Seker M, Aliyev A, et al. Oncol Res Treat. Epub 2018 Aug 20. • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Aliyev A. Cancer Chemother Pharmacol.2019 Jan; Epub 2018 Oct 30. • Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM, Aliyev A, Celik RS. Curr Probl Cancer.2019 Jul 29. pii: currproblcancer.2019.06.009. • Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience. Tarik Demir, Murat Araz, Altay Aliyev. Medicine Science International Medicine Journal. • Oral presentations 

Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.

He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.

He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.

ヤロスラヴ・トヴァルゼク博士はロボット手術の専門家です。トヴァルゼク博士は、オリジナルのダ・ヴィンチロボットを製造するアメリカの企業であるインテュイティブ・サージカルの認定リーディングエキスパートです。医師は、美容外科学会と肥満外科学会の会員です。

トヴァルゼク博士は、チェコ共和国のセント・ズディスラヴァ病院にあるロボット手術センターを率いています。医師はこれまでに3,500回以上のロボット手術を行ってきました。その中には次のものが含まれます：

• 勃起機能を維持した前立腺摘出術
• 経口手術（鼻咽頭、喉頭、気管、口腔の腫瘍切除）
• 甲状腺切除
• 腎摘出術
• 減量手術（肥満の外科的治療）。

Dr. Asawadech Sanbua

Medical Radiation​ Oncologist

• Passed palliative care training at the Karunrak Center. Khon Kaen University
  
   
• Certificate of oncotherm
  
   
• Expert in treating cancer with oncothermia machines (or hyperthermia machine) 5 years experience.
  
   
• 14 years of experience working in radiotherapy. Able to plan treatment (Planning 2D, 3D, IMRT, VMAT)
  
   
• Can provide chemical treatment, Chemotherapy, targeted drugs therapy) Immunotherapy (Immunotherapy) 

Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.

He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.

Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.